KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Notes Payables: 2014-2015

Historic Notes Payables for Sarepta Therapeutics (SRPT) over the last 1 years, with Dec 2015 value amounting to $2.5 million.

  • Sarepta Therapeutics' Notes Payables rose 0.04% to $2.5 million in Q4 2015 from the same period last year, while for Dec 2015 it was $2.5 million, marking a year-over-year increase of 0.04%. This contributed to the annual value of $2.5 million for FY2015, which is 0.04% up from last year.
  • Sarepta Therapeutics' Notes Payables amounted to $2.5 million in Q4 2015, which was up 1.59% from $2.5 million recorded in Q3 2015.
  • Sarepta Therapeutics' Notes Payables' 5-year high stood at $4.9 million during Q2 2015, with a 5-year trough of $2.4 million in Q3 2014.
  • In the last 2 years, Sarepta Therapeutics' Notes Payables had a median value of $2.5 million in 2014 and averaged $3.3 million.
  • Data for Sarepta Therapeutics' Notes Payables shows a peak YoY increased of 1.61% (in 2015) over the last 5 years.
  • Quarterly analysis of 2 years shows Sarepta Therapeutics' Notes Payables stood at $2.5 million in 2014, then increased by 0.04% to $2.5 million in 2015.
  • Its Notes Payables was $2.5 million in Q4 2015, compared to $2.5 million in Q3 2015 and $4.9 million in Q2 2015.